43 related articles for article (PubMed ID: 14719226)
1. Scleromalacia perforans as an early manifestation of late-onset rheumatoid arthritis: a case-based review.
de Figueiredo LQ; de Andrade Lopes FO; Franco AS; Giardini HAM; Guedes LKN; Bonfiglioli KR; Shimabuco AY; de Medeiros Ribeiro AC; Domiciano DS
Rheumatol Int; 2024 Jun; 44(6):1165-1173. PubMed ID: 37925382
[TBL] [Abstract][Full Text] [Related]
2. Authors' reply to Whitlock: Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence.
Ignatowski TA; Spengler RN; Tobinick E
CNS Drugs; 2014 Dec; 28(12):1207-13. PubMed ID: 25373629
[No Abstract] [Full Text] [Related]
3. [Not Available].
Xie JS; Kaplan AJ
CMAJ; 2024 Mar; 196(11):E392-E393. PubMed ID: 38527748
[No Abstract] [Full Text] [Related]
4. Etanercept-associated episcleritis: a pediatric case report of a paradoxical adverse reaction and review of the literature.
Küçükali B; Gezgin Yıldırım D; Esmeray Şenol P; Özdemir HB; Bakkaloğlu SA
Clin Rheumatol; 2024 Feb; 43(2):799-808. PubMed ID: 37845415
[TBL] [Abstract][Full Text] [Related]
5. Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review.
Dammacco R; Guerriero S; Alessio G; Dammacco F
Int Ophthalmol; 2022 Feb; 42(2):689-711. PubMed ID: 34802085
[TBL] [Abstract][Full Text] [Related]
6. Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review.
Sota J; Girolamo MM; Frediani B; Tosi GM; Cantarini L; Fabiani C
Ophthalmol Ther; 2021 Dec; 10(4):777-813. PubMed ID: 34476773
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study.
Rudwaleit M; Rødevand E; Holck P; Vanhoof J; Kron M; Kary S; Kupper H
Ann Rheum Dis; 2009 May; 68(5):696-701. PubMed ID: 18662932
[TBL] [Abstract][Full Text] [Related]
8. Treatment of rheumatoid arthritis with etanercept.
Genovese MC; Kremer JM
Rheum Dis Clin North Am; 2004 May; 30(2):311-28, vi-vii. PubMed ID: 15172043
[TBL] [Abstract][Full Text] [Related]
9. Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary?
Tiliakos AN; Tiliakos NA
J Rheumatol; 2003 Dec; 30(12):2727. PubMed ID: 14719226
[No Abstract] [Full Text] [Related]
10. Etanercept therapy in children with treatment-resistant uveitis.
Reiff A; Takei S; Sadeghi S; Stout A; Shaham B; Bernstein B; Gallagher K; Stout T
Arthritis Rheum; 2001 Jun; 44(6):1411-5. PubMed ID: 11407702
[TBL] [Abstract][Full Text] [Related]
11. Treating leukocytoclastic vasculitis associated with etanercept therapy. Is it necessary to stop etanercept?
Juan A; Ribas B; Nadal C; Ros I
J Rheumatol; 2005 Oct; 32(10):2061; author reply 2061-2. PubMed ID: 16206372
[No Abstract] [Full Text] [Related]
12. Etanercept (Enbrel) -- an update.
Goffe B
Skin Therapy Lett; 2004 Dec-2005 Jan; 9(10):1-4, 9. PubMed ID: 15657632
[TBL] [Abstract][Full Text] [Related]
13. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
[TBL] [Abstract][Full Text] [Related]
14. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
